Free tool
FAERS Monitor: Vabysmo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761235 or its brand name (Vabysmo, Faricimab-Svoa). Reports on generic versions are filed under their own applications.
Reports
8,868
Serious
4,784
54% of reports
Hospitalization
539
Death reported
513
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,963
- no adverse event1,970
- retinal thickening1,471
- visual impairment856
- optical coherence tomography abnormal776
- death466
- drug ineffective380
- eye inflammation360
- uveitis353
- visual acuity tests abnormal346
- visual acuity reduced332
- blindness275
- vitritis269
- endophthalmitis266
- vision blurred245
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 10 |
| 2022 | 254 |
| 2023 | 771 |
| 2024 | 3,756 |
| 2025 | 1,735 |
| 2026 | 2,338 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,291 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| optical coherence tomography abnormalSignal | 776 | 21923.6 | 17520.9 | 1,659,481 |
| retinal thickeningSignal | 1,471 | 17542.4 | 15150.8 | 3,072,753 |
| visual acuity tests abnormalSignal | 346 | 3910.1 | 3298.2 | 509,259 |
| vitritisSignal | 269 | 403.0 | 354.8 | 91,879 |
| endophthalmitisSignal | 266 | 110.0 | 97.4 | 27,360 |
| eye inflammationSignal | 360 | 93.0 | 83.8 | 31,439 |
| uveitisSignal | 353 | 63.3 | 57.1 | 21,050 |
| no adverse eventSignal | 1,970 | 26.1 | 25.1 | 47,342 |
| visual acuity reducedSignal | 332 | 23.9 | 21.5 | 7,214 |
| visual impairmentSignal | 856 | 16.5 | 15.5 | 12,428 |
| blindnessSignal | 275 | 16.1 | 14.3 | 3,864 |
| off label useSignal | 2,963 | 8.0 | 7.8 | 19,016 |
| vision blurredSignal | 245 | 4.2 | 3.7 | 606 |
| death | 466 | 1.3 | 1.2 | 30 |
| drug ineffective | 380 | 0.7 | 0.6 | 59 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.